Germany's IQWiG finds no proof of added benefit for Bayer's Eylea
There was disappointment for German drug major Bayer (BAYN: DE), when the German Institute for Quality and Efficiency in Health Care (IQWiG) gave its opinion that its wet age-related macular degeneration treatment Eylea (aflibercept) offers no added benefit over the current standard therapy.
Such an added benefit cannot be derived from the dossier, however, as the manufacturer did not submit any suitable data for this comparison, the IQWiG said following its assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG). The drug has been approved in Germany for this indication since November 2012.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze